Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Quince Therapeutics, Inc. | Director | Employee Stock Option (right to buy) | 13.5K | Jun 5, 2024 | Direct | ||
REATA PHARMACEUTICALS INC | EVP, Chief R&D Officer | Class A common stock | 0 | $172.03 | Sep 26, 2023 | Direct | |
REATA PHARMACEUTICALS INC | EVP, Chief R&D Officer | Employee Stock Option (right to buy) | 0 | Sep 26, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
QNCX | Quince Therapeutics, Inc. | Jun 5, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director |
QNCX | Quince Therapeutics, Inc. | Feb 15, 2024 | 1 | $0 | 4 | Feb 15, 2024 | Director |
QNCX | Quince Therapeutics, Inc. | Feb 15, 2024 | 0 | $0 | 3 | Feb 15, 2024 | Director |
RETA | REATA PHARMACEUTICALS INC | Sep 26, 2023 | 2 | $0 | 4 | Sep 26, 2023 | EVP, Chief R&D Officer |
RETA | REATA PHARMACEUTICALS INC | Jun 12, 2023 | 2 | $0 | 4 | Jun 14, 2023 | EVP, Chief R&D Officer |
RETA | REATA PHARMACEUTICALS INC | Jun 12, 2023 | 0 | $0 | 3 | Jun 14, 2023 | EVP, Chief R&D Officer |